2026 Q1 -tulosraportti
42 päivää sitten
‧36 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·20 t sittenIt's like watching paint dry here in this stock. When will management start communicating with the market and issue a statement regarding all these conferences they have attended in recent months. Revenue is terrible, updates from the company are absent and the price falls every single day! Looks like it will be a tough summer unfortunately!
·19.6.Anbjørn Øglend, Norway's 4th richest tax refugee to Switzerland (https://www.finansavisen.no/finans/2024/12/04/8214780/dette-er-de-rikeste-sveits-flyktningene), has through his investment company Prima Investment AS (https://www.proff.no/aksjonærer/bedrift/prima-investment-as/920058493) increased his stake in Lytix from approx 26k in February '26 (first purchase) to approx 331k yesterday. Last purchase 18.06., + 58 857 shares.Back it up with facts? Rabdav/Davrab and Stockwizard on FA Forum have served us relatively balanced posts that give us insight into mechanisms and opportunities. Rekdal & co have been present at all available oncological conferences and exhibition venues for their oncolytic platform. Merck "needs" LTX-315 as an extension of its Keytruda patent. LTX-315 fits like a glove in Johnson&Johnson's portfolio. Others can lurk like a pike in the reeds. And the bonus is LTX-401, validated through -315, and guaranteed to be on the radar for the big players. These are the feelings in my head, but there are so many arrows pointing within +/-15 degrees of success that I myself believe it looks good for my own investment. Therefore, I - for my part - have a large investment in Lytix, and will continue to acquire what I think are extremely cheap shares for a future gain. How big the gain will be is entirely up to the technology, the negotiation team, and the interest from Big Pharma. I feel great security in this investment.
·18.6. · MuokattuFascinating that Lytix has 825 shareholders on Nordnet while e.g. oncoinvent has 3400. Circio has over 16000. The turnover is currently record low. It's clear that the management is unable to convey to the market what they are doing. Even the community in here is starting to doubt.
there might be a reason why the stock price is low. yes, that few know the potential of the stock.. thus a buying argument as I see it.... Regardless of what people think or know.... if Neolipa releases top-line data with 27 patients in 2026 with equally good numbers as for n=9, Bigpharma will become interested.... and then interest will increase regardless.
·12.6.Is anyone getting an answer from Lytix as to why they think it is appropriate to have a meeting with the FDA to evaluate the phase 2 data from NeoLIPA regarding study design for phase 3 execution, BEFORE top line data from NeoLIPA is available??? Sounds very strange. It must be difficult for the authorities to discuss plans for study design BEFORE they have even received the full dataset from such a small number of patients as 27 in a neoadjuvant setting. And one would preferably have submitted the data and presented thoughts and possibilities in advance of the meeting, I would think. Premature? TTT as Rekdal says when planning for phase 3 with meetings with the FDA after data is available, alignment, CRO, etc etc. For Verrica, it takes more than 2 years from when the phase 2 data from a large dataset with approximately 100 patients became available. There is little to suggest Lytix will manage it any faster, given their track record of previous failures in all guidances, and the fact that Lytix will also be broke again in 2027. Here we are talking about a mega emission, perhaps towards a special investor / fund? Is it just something they say without having thought it through? In the same way they rush out and say that Verrica is planning for the start of phase 3 this year, while Verrica will not confirm this, and soon it will be summer holiday...
The prediction from Molbre that we on Friday the 12th would end at six kroner is less precise than Lytix's forecasts. That's something, at least.- ·10.6. · MuokattuUnfortunately, there's not much more to write soon than "I told you so." When one starts applying for patent extensions under the protection that it should be granted together with krill, cod liver oil, or chitosan, hope begins to hang by a thread. Why won't the company answer about the patent situation and talk about this? Look and learn from Circio. They are open and forward-leaning. The same goes for the cash reserves. Where Circio says this is probably the last time we raise money, Lytix is silent. Emissions are coming and will come like a bolt from the blue. Unfortunately, there is no hope for a partner from results on small old single-arm studies with very few patients from the last 20 years back in time. Something more is needed. And the key value driver was deprioritized. They delayed over a year in implementing measures to increase the recruitment rate despite questions being raised about this early on, and it was dismissed as everything going completely according to plan. An amateurish and costly mistake. The company already has a partner, and there, too, everything is going smoothly according to the congregation. But the fact is, as I have always written, that there will be no start of Phase 3 this year. It was silent about this at the last investor conference, and Verrica will not finance this themselves because they lack capital, even with a low bar from the FDA. Lytix tries to hype by saying that Verrica plans to be able to start Phase 3 in 2026, but Verrica itself has not said this and denies the claim upon inquiry. Why is Lytix desperately trying to make it sound like Phase 3 for Verrica is starting soon? On Hegnar's fairground, they write that they hope to buy cheap shares at 9kr, but that doesn't seem to be true. The share is weak because there is no buy side, so it falls to 8, perhaps soon 7 and 6 before the next emission. Why won't the company be listed on the main list if they want new investors and greater trading volume in the share? Is it perhaps because the ground has already been surveyed and it's dead given that the patent situation is so weak, and the key value driver is far in the distance and with uncertain value given that it takes such a terribly long time to handpick these few patients? Could it be that today's shareholders will soon be heavily diluted when the company needs capital for Phase 3 in melanoma, or do you think the company can afford to wait another 1 or 2 years after the Phase 2 data are ready to find a partner? Just look at Verrica, which with strong Phase 2 data from a large study has to spend almost 3 years from there to find a partner and get Phase 3 started. It wasn't just 27 patients over 2 years there.... It's no wonder the price is falling and will continue to fall. The next thing coming is the summer holiday and then another report of weak recruitment in NeoLipa. But it doesn't matter according to the congregation whether data from the key value driver comes in H1 2026, mid 2026, late 2026 or in 2027. It's only 1 year more or less, and they have money all the way until 2027.That is correct. Difficult topics or critical questions are not answered. But as some users then do instead: Ask ChatGPT and ask it to come up with some positive answers to this. Unfortunately, that becomes pure fiction and not something one should put any stock in. But I see some are trying to get Lytix into the Radium podcast. Then they can shed light on everything I mention as weaknesses and uncertainties. Not least how a phase 3 study is to be financed when one presumably doesn't have time to wait 1 - 2 years to negotiate with partners
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
42 päivää sitten
‧36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·20 t sittenIt's like watching paint dry here in this stock. When will management start communicating with the market and issue a statement regarding all these conferences they have attended in recent months. Revenue is terrible, updates from the company are absent and the price falls every single day! Looks like it will be a tough summer unfortunately!
- ·19.6.Anbjørn Øglend, Norway's 4th richest tax refugee to Switzerland (https://www.finansavisen.no/finans/2024/12/04/8214780/dette-er-de-rikeste-sveits-flyktningene), has through his investment company Prima Investment AS (https://www.proff.no/aksjonærer/bedrift/prima-investment-as/920058493) increased his stake in Lytix from approx 26k in February '26 (first purchase) to approx 331k yesterday. Last purchase 18.06., + 58 857 shares.Back it up with facts? Rabdav/Davrab and Stockwizard on FA Forum have served us relatively balanced posts that give us insight into mechanisms and opportunities. Rekdal & co have been present at all available oncological conferences and exhibition venues for their oncolytic platform. Merck "needs" LTX-315 as an extension of its Keytruda patent. LTX-315 fits like a glove in Johnson&Johnson's portfolio. Others can lurk like a pike in the reeds. And the bonus is LTX-401, validated through -315, and guaranteed to be on the radar for the big players. These are the feelings in my head, but there are so many arrows pointing within +/-15 degrees of success that I myself believe it looks good for my own investment. Therefore, I - for my part - have a large investment in Lytix, and will continue to acquire what I think are extremely cheap shares for a future gain. How big the gain will be is entirely up to the technology, the negotiation team, and the interest from Big Pharma. I feel great security in this investment.
- ·18.6. · MuokattuFascinating that Lytix has 825 shareholders on Nordnet while e.g. oncoinvent has 3400. Circio has over 16000. The turnover is currently record low. It's clear that the management is unable to convey to the market what they are doing. Even the community in here is starting to doubt.there might be a reason why the stock price is low. yes, that few know the potential of the stock.. thus a buying argument as I see it.... Regardless of what people think or know.... if Neolipa releases top-line data with 27 patients in 2026 with equally good numbers as for n=9, Bigpharma will become interested.... and then interest will increase regardless.
- ·12.6.Is anyone getting an answer from Lytix as to why they think it is appropriate to have a meeting with the FDA to evaluate the phase 2 data from NeoLIPA regarding study design for phase 3 execution, BEFORE top line data from NeoLIPA is available??? Sounds very strange. It must be difficult for the authorities to discuss plans for study design BEFORE they have even received the full dataset from such a small number of patients as 27 in a neoadjuvant setting. And one would preferably have submitted the data and presented thoughts and possibilities in advance of the meeting, I would think. Premature? TTT as Rekdal says when planning for phase 3 with meetings with the FDA after data is available, alignment, CRO, etc etc. For Verrica, it takes more than 2 years from when the phase 2 data from a large dataset with approximately 100 patients became available. There is little to suggest Lytix will manage it any faster, given their track record of previous failures in all guidances, and the fact that Lytix will also be broke again in 2027. Here we are talking about a mega emission, perhaps towards a special investor / fund? Is it just something they say without having thought it through? In the same way they rush out and say that Verrica is planning for the start of phase 3 this year, while Verrica will not confirm this, and soon it will be summer holiday...The prediction from Molbre that we on Friday the 12th would end at six kroner is less precise than Lytix's forecasts. That's something, at least.
- ·10.6. · MuokattuUnfortunately, there's not much more to write soon than "I told you so." When one starts applying for patent extensions under the protection that it should be granted together with krill, cod liver oil, or chitosan, hope begins to hang by a thread. Why won't the company answer about the patent situation and talk about this? Look and learn from Circio. They are open and forward-leaning. The same goes for the cash reserves. Where Circio says this is probably the last time we raise money, Lytix is silent. Emissions are coming and will come like a bolt from the blue. Unfortunately, there is no hope for a partner from results on small old single-arm studies with very few patients from the last 20 years back in time. Something more is needed. And the key value driver was deprioritized. They delayed over a year in implementing measures to increase the recruitment rate despite questions being raised about this early on, and it was dismissed as everything going completely according to plan. An amateurish and costly mistake. The company already has a partner, and there, too, everything is going smoothly according to the congregation. But the fact is, as I have always written, that there will be no start of Phase 3 this year. It was silent about this at the last investor conference, and Verrica will not finance this themselves because they lack capital, even with a low bar from the FDA. Lytix tries to hype by saying that Verrica plans to be able to start Phase 3 in 2026, but Verrica itself has not said this and denies the claim upon inquiry. Why is Lytix desperately trying to make it sound like Phase 3 for Verrica is starting soon? On Hegnar's fairground, they write that they hope to buy cheap shares at 9kr, but that doesn't seem to be true. The share is weak because there is no buy side, so it falls to 8, perhaps soon 7 and 6 before the next emission. Why won't the company be listed on the main list if they want new investors and greater trading volume in the share? Is it perhaps because the ground has already been surveyed and it's dead given that the patent situation is so weak, and the key value driver is far in the distance and with uncertain value given that it takes such a terribly long time to handpick these few patients? Could it be that today's shareholders will soon be heavily diluted when the company needs capital for Phase 3 in melanoma, or do you think the company can afford to wait another 1 or 2 years after the Phase 2 data are ready to find a partner? Just look at Verrica, which with strong Phase 2 data from a large study has to spend almost 3 years from there to find a partner and get Phase 3 started. It wasn't just 27 patients over 2 years there.... It's no wonder the price is falling and will continue to fall. The next thing coming is the summer holiday and then another report of weak recruitment in NeoLipa. But it doesn't matter according to the congregation whether data from the key value driver comes in H1 2026, mid 2026, late 2026 or in 2027. It's only 1 year more or less, and they have money all the way until 2027.That is correct. Difficult topics or critical questions are not answered. But as some users then do instead: Ask ChatGPT and ask it to come up with some positive answers to this. Unfortunately, that becomes pure fiction and not something one should put any stock in. But I see some are trying to get Lytix into the Radium podcast. Then they can shed light on everything I mention as weaknesses and uncertainties. Not least how a phase 3 study is to be financed when one presumably doesn't have time to wait 1 - 2 years to negotiate with partners
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 |
2026 Q1 -tulosraportti
42 päivää sitten
‧36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 21.5. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 18.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 15.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·20 t sittenIt's like watching paint dry here in this stock. When will management start communicating with the market and issue a statement regarding all these conferences they have attended in recent months. Revenue is terrible, updates from the company are absent and the price falls every single day! Looks like it will be a tough summer unfortunately!
- ·19.6.Anbjørn Øglend, Norway's 4th richest tax refugee to Switzerland (https://www.finansavisen.no/finans/2024/12/04/8214780/dette-er-de-rikeste-sveits-flyktningene), has through his investment company Prima Investment AS (https://www.proff.no/aksjonærer/bedrift/prima-investment-as/920058493) increased his stake in Lytix from approx 26k in February '26 (first purchase) to approx 331k yesterday. Last purchase 18.06., + 58 857 shares.Back it up with facts? Rabdav/Davrab and Stockwizard on FA Forum have served us relatively balanced posts that give us insight into mechanisms and opportunities. Rekdal & co have been present at all available oncological conferences and exhibition venues for their oncolytic platform. Merck "needs" LTX-315 as an extension of its Keytruda patent. LTX-315 fits like a glove in Johnson&Johnson's portfolio. Others can lurk like a pike in the reeds. And the bonus is LTX-401, validated through -315, and guaranteed to be on the radar for the big players. These are the feelings in my head, but there are so many arrows pointing within +/-15 degrees of success that I myself believe it looks good for my own investment. Therefore, I - for my part - have a large investment in Lytix, and will continue to acquire what I think are extremely cheap shares for a future gain. How big the gain will be is entirely up to the technology, the negotiation team, and the interest from Big Pharma. I feel great security in this investment.
- ·18.6. · MuokattuFascinating that Lytix has 825 shareholders on Nordnet while e.g. oncoinvent has 3400. Circio has over 16000. The turnover is currently record low. It's clear that the management is unable to convey to the market what they are doing. Even the community in here is starting to doubt.there might be a reason why the stock price is low. yes, that few know the potential of the stock.. thus a buying argument as I see it.... Regardless of what people think or know.... if Neolipa releases top-line data with 27 patients in 2026 with equally good numbers as for n=9, Bigpharma will become interested.... and then interest will increase regardless.
- ·12.6.Is anyone getting an answer from Lytix as to why they think it is appropriate to have a meeting with the FDA to evaluate the phase 2 data from NeoLIPA regarding study design for phase 3 execution, BEFORE top line data from NeoLIPA is available??? Sounds very strange. It must be difficult for the authorities to discuss plans for study design BEFORE they have even received the full dataset from such a small number of patients as 27 in a neoadjuvant setting. And one would preferably have submitted the data and presented thoughts and possibilities in advance of the meeting, I would think. Premature? TTT as Rekdal says when planning for phase 3 with meetings with the FDA after data is available, alignment, CRO, etc etc. For Verrica, it takes more than 2 years from when the phase 2 data from a large dataset with approximately 100 patients became available. There is little to suggest Lytix will manage it any faster, given their track record of previous failures in all guidances, and the fact that Lytix will also be broke again in 2027. Here we are talking about a mega emission, perhaps towards a special investor / fund? Is it just something they say without having thought it through? In the same way they rush out and say that Verrica is planning for the start of phase 3 this year, while Verrica will not confirm this, and soon it will be summer holiday...The prediction from Molbre that we on Friday the 12th would end at six kroner is less precise than Lytix's forecasts. That's something, at least.
- ·10.6. · MuokattuUnfortunately, there's not much more to write soon than "I told you so." When one starts applying for patent extensions under the protection that it should be granted together with krill, cod liver oil, or chitosan, hope begins to hang by a thread. Why won't the company answer about the patent situation and talk about this? Look and learn from Circio. They are open and forward-leaning. The same goes for the cash reserves. Where Circio says this is probably the last time we raise money, Lytix is silent. Emissions are coming and will come like a bolt from the blue. Unfortunately, there is no hope for a partner from results on small old single-arm studies with very few patients from the last 20 years back in time. Something more is needed. And the key value driver was deprioritized. They delayed over a year in implementing measures to increase the recruitment rate despite questions being raised about this early on, and it was dismissed as everything going completely according to plan. An amateurish and costly mistake. The company already has a partner, and there, too, everything is going smoothly according to the congregation. But the fact is, as I have always written, that there will be no start of Phase 3 this year. It was silent about this at the last investor conference, and Verrica will not finance this themselves because they lack capital, even with a low bar from the FDA. Lytix tries to hype by saying that Verrica plans to be able to start Phase 3 in 2026, but Verrica itself has not said this and denies the claim upon inquiry. Why is Lytix desperately trying to make it sound like Phase 3 for Verrica is starting soon? On Hegnar's fairground, they write that they hope to buy cheap shares at 9kr, but that doesn't seem to be true. The share is weak because there is no buy side, so it falls to 8, perhaps soon 7 and 6 before the next emission. Why won't the company be listed on the main list if they want new investors and greater trading volume in the share? Is it perhaps because the ground has already been surveyed and it's dead given that the patent situation is so weak, and the key value driver is far in the distance and with uncertain value given that it takes such a terribly long time to handpick these few patients? Could it be that today's shareholders will soon be heavily diluted when the company needs capital for Phase 3 in melanoma, or do you think the company can afford to wait another 1 or 2 years after the Phase 2 data are ready to find a partner? Just look at Verrica, which with strong Phase 2 data from a large study has to spend almost 3 years from there to find a partner and get Phase 3 started. It wasn't just 27 patients over 2 years there.... It's no wonder the price is falling and will continue to fall. The next thing coming is the summer holiday and then another report of weak recruitment in NeoLipa. But it doesn't matter according to the congregation whether data from the key value driver comes in H1 2026, mid 2026, late 2026 or in 2027. It's only 1 year more or less, and they have money all the way until 2027.That is correct. Difficult topics or critical questions are not answered. But as some users then do instead: Ask ChatGPT and ask it to come up with some positive answers to this. Unfortunately, that becomes pure fiction and not something one should put any stock in. But I see some are trying to get Lytix into the Radium podcast. Then they can shed light on everything I mention as weaknesses and uncertainties. Not least how a phase 3 study is to be financed when one presumably doesn't have time to wait 1 - 2 years to negotiate with partners
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt